Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Xiaoge Kou"'
Autor:
Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Objective To explore the efficacy of serplulimab plus chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with liver metastases. Methods A post hoc exploratory analysis of ASTRUM‐007 study was performed, focusing on the asso
Externí odkaz:
https://doaj.org/article/853c821061684aecbd227cf8265e2157
Autor:
Yiqun Li, Yanfeng Wang, Ning Li, Xinjun Liang, Shu Zhang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Binghe Xu, Jing Huang, Ningning Wang
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 8, Pp 988-990 (2022)
Externí odkaz:
https://doaj.org/article/ef9952c7921c4dc8befe482fde05f0d6
Autor:
Ning Li, Shu Zhang, Yan Song, Jing Huang, Qun Li, Xinjun Liang, Qingxia Fan, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Xiaofei Wang, Yiwei Dou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Irinotecan is used as second-line treatment in advanced gastric or gastroesophageal junction (G/GEJ) cancer. The role of anti-programmed death-1 (PD-1) antibody plus irinotecan, in this setting and population is unclear.Methods This multic
Externí odkaz:
https://doaj.org/article/2ea8979f98df4249b644f01ca978d6f8
Autor:
Bo Zhang, Yan Song, Suxia Luo, Xianli Yin, Enxiao Li, Hui Wang, Yifu He, Zhihui Liu, Qingxia Fan, Xinjun Liang, Yongqian Shu, Yunpeng Liu, Nong Xu, Shu Zhang, Zhixiang Zhuang, Jingdong Zhang, Xiaoge Kou, Fen Wang, Xiaodong Zhu, Jing Huang
Publikováno v:
Journal of Clinical Oncology. 41:799-799
799 Background: Pucotenlimab is a humanized IgG4 anti-PD-1 monoclonal antibody with an engineered Fc domain. We aim to assess the efficacy and safety of pucotenlimab, and potential predictive biomarkers of response in patients with previously treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70d2e331e206e8502dd25ae7a5531f38
https://doi.org/10.1200/jco.2023.41.4_suppl.799
https://doi.org/10.1200/jco.2023.41.4_suppl.799
Autor:
Yan Song, Qingxia Fan, Yunpeng Liu, Jingdong Zhang, Xianli Yin, Yongqian Shu, Enxiao Li, Hui Wang, Jing Huang, Xinjun Liang, Xiaoge Kou, Shengmian Li, Zhihui Liu, Fen Wang, Nong Xu, Yifu He, Xiao-Dong Zhu, Shu Zhang, Suxia Luo, Zhixiang Zhuang
Publikováno v:
Journal of Clinical Oncology. 39:2572-2572
2572 Background: The subsequent treatment choices are limited for the patients with advanced solid tumors who had failed the standard therapies. PD-1 blockade monotherapy demonstrated robust antitumor activity in patients with MSI-H/dMMR. The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c07b05bce42fc580da23cdce962b41c
https://doi.org/10.1200/jco.2021.39.15_suppl.2572
https://doi.org/10.1200/jco.2021.39.15_suppl.2572
Autor:
Haijun Zhong, Jing Huang, Shu Zhang, Xianli Yin, Xiaoge Kou, Qingxia Fan, Ning Li, Xinjun Liang, Yunpeng Liu, Yan Song, Jingdong Zhang, Zhixiang Zhuang, Lan Mu
Publikováno v:
Journal of Clinical Oncology. 38:4524-4524
4524 Background: Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We investigated HX008, an Anti-PD1 Antibody, with irinotecan in patients with advanced gastric or gastro-oesopha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62f0ac4c36e3c569c107c7128c35c38c
https://doi.org/10.1200/jco.2020.38.15_suppl.4524
https://doi.org/10.1200/jco.2020.38.15_suppl.4524
Publikováno v:
Journal of Cancer Research & Therapeutics; Aug2014 Special Issue, Vol. 10 Issue S5, pC46-C51, 6p